ArticleFrontiers in bioengineering and biotechnology2020
An Injectable Hydrogel Platform for Sustained Delivery of Anti-inflammatory Nanocarriers and Induction of Regulatory T Cells in Atherosclerosis.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction.Frontiers in immunology · 2024Pooled it
- Selective elimination of mast cells via Siglec-6-targeted nanodelivery of drug payload.The Journal of allergy and clinical immunology · 2026Article
- Functional hydrogels in cardiovascular therapy: Design, applications and clinical challenges (Review).International journal of molecular medicine · 2026Review
- Filomicelle-Embedded Composite Hydrogels for Localized Gelation Within the Anterior Chamber of the Eye.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Emerging Gel Technologies for Atherosclerosis Research and Intervention.Gels (Basel, Switzerland) · 2026Review
- Piezoelectric electrospun scaffold incorporating ibuprofen loaded ultrasound-responsive mesoporous silica nanoparticles for tissue regeneration.RSC advances · 2025Article
- Demystifying the management of cancer through smart nano-biomedicine via regulation of reactive oxygen species.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Precise modulation and use of reactive oxygen species for immunotherapy.Science advances · 2024Review
- Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches.Drug delivery and translational research · 2023Review
- Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms.Frontiers in bioengineering and biotechnology · 2023Review
- ROS-Responsive Glycopolymeric Nanoparticles for Enhanced Drug Delivery to Macrophages.Macromolecular bioscience · 2022Article
- Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications.Pharmaceutics · 2022Review
- Pi-stacking Enhances Stability, Scalability of Formation, Control over Flexibility and Circulation Time of Polymeric Filaments.Advanced nanobiomed research · 2021Article
- Innovations in Disease State Responsive Soft Materials for Targeting Extracellular Stimuli Associated with Cancer, Cardiovascular Disease, Diabetes, and Beyond.Advanced materials (Deerfield Beach, Fla.) · 2021Review
- Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases.Drug delivery and translational research · 2021Review
- The Combination of Morphology and Surface Chemistry Defines the Immunological Identity of Nanocarriers in Human Blood.Advanced therapeutics · 2021Article
- Just add water: hydratable, morphologically diverse nanocarrier powders for targeted delivery.Nanoscale · 2021Article
- Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.JCI insight · 2021Article
- Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.Advanced drug delivery reviews · 2021Review
- Nanotechnology for Targeted Therapy of Atherosclerosis.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Chronic unresolved vascular inflammation is a critical factor in the development of atherosclerosis. Cardiovascular immunotherapy has therefore become a recent focus for treatment, with the objective to develop approaches that can suppress excessive inflammatory responses by modulating specific immune cell populations. A benefit of such immunomodulatory strategies is that low dosage stimulation of key immune cell populations, like antigen presenting cells, can subsequently propagate strong proliferation and therapeutic responses from effector cells. We have previously demonstrated that intravenous injections of anti-inflammatory nanocarriers provided atheroprotection that was mediated by regulatory T cells (Tregs) upregulated in lymphoid organs and atherosclerotic lesions. Here, we demonstrate an injectable filamentous hydrogel depot (FM-depot) engineered for low dosage, sustained delivery of anti-inflammatory nanocarriers. The bioactive form of vitamin D (aVD; 1, 25-Dihydroxyvitamin D3), which inhibits pro-inflammatory transcription factor NF-κB via the intracellular nuclear hormone receptor vitamin D receptor (VDR), was stably loaded into poly(ethylene glycol)-block-poly(propylene sulfide) (PEG-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.